Boston Scientific Neuromodulation Corporation Sustainability Profile
Boston Scientific Neuromodulation Corporation, a subsidiary of Boston Scientific Corporation, is a leading player in the medical technology industry, headquartered in the United States. Founded in 1979, the company has made significant strides in developing innovative neuromodulation therapies aimed at treating chronic pain and neurological disorders. With a strong presence in North America, Europe, and Asia, Boston Scientific Neuromodulation offers a diverse range of products, including spinal cord stimulators and deep brain stimulation systems. These advanced solutions are designed to improve patient outcomes through targeted nerve stimulation, setting the company apart in a competitive market. Recognised for its commitment to research and development, Boston Scientific Neuromodulation has achieved numerous milestones, solidifying its position as a trusted leader in the field of neuromodulation therapies.
DitchCarbon Score
How does Boston Scientific Neuromodulation Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boston Scientific Neuromodulation Corporation's score of 92 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boston Scientific Neuromodulation Corporation, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Boston Scientific Corporation, which may influence its climate commitments and emissions reporting. As part of its corporate family, Boston Scientific Neuromodulation Corporation inherits climate initiatives and targets from Boston Scientific Corporation. However, there are no documented reduction targets or significant climate pledges specific to the Neuromodulation division. The overarching commitments and performance metrics are sourced from Boston Scientific Corporation, which is responsible for setting the climate strategy and reporting. While specific emissions figures are not provided, the company is expected to align with the sustainability goals and initiatives of its parent organisation. This includes participation in frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which are cascaded down from Boston Scientific Corporation. In summary, Boston Scientific Neuromodulation Corporation is currently in a position of inheriting climate commitments from its parent company, with no specific emissions data or reduction targets reported at this level.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Boston Scientific Neuromodulation Corporation's Industry?
How Carbon Intensive is Boston Scientific Neuromodulation Corporation's Location?
Boston Scientific Neuromodulation Corporation's Scope 3 Categories Breakdown
Boston Scientific Neuromodulation Corporation's Scope 3 emissions, which increased by 28% last year and decreased by approximately 7% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 57% of Scope 3 emissions.
Top Scope 3 Categories
Boston Scientific Neuromodulation Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Boston Scientific Neuromodulation Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
